Share | Jotup

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

Retrieved on:

Tuesday, April 2, 2024

HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Aditxt Inc. (NASDAQ: ADTX) (“Aditxt”), a Richmond, Virginia- based company dedicated to discovering, developing, and deploying promising health innovation, through its wholly-owned subsidiary, Adivir, Inc. (“Adivir” or the “Buyer”), agreed to acquire all of the issued and outstanding Class A common shares (the "Appili Shares") of Appili by way of a court-approved plan of arrangement under the Canada Business Corporations Act (the "Transaction").

Key Points:

We welcome this new chapter, confident that together, we will achieve even greater heights in deploying innovative healthcare solutions.” said Dr. Don Cilla, President and CEO of Appili Therapeutics.
Under the terms of the Arrangement Agreement, Adivir will acquire all of the issued and outstanding Appili Shares, with each Appili Shareholder receiving the Transaction Consideration.
The Transaction is subject to the approval of at least two-thirds of the votes cast by the Appili Shareholders at the Appili Meeting.
Bloom Burton Securities Inc. acted as financial advisor to the Appili Board and BDO Canada LLP acted as independent financial advisor to the Appili Special Committee.

Genetron Health Announces Completion of Going Private Transaction

Retrieved on:

Thursday, March 28, 2024

Slate, Bank, GTH, Letter, Form 6-K, Committee, Form, Share, LLP, ADS, Security (finance), Consortium, Parent, King & Wood Mallesons, BNY Mellon

As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.

Key Points:

As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.
The deregistration will become effective 90 days after the filing of the Form 25 or such shorter period as may be determined by the SEC.
The Company intends to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, by filing a Form 15 with the SEC in approximately ten days following the filing of the Form 25.
Skadden, Arps, Slate, Meagher & Flom LLP is serving as U.S. legal counsel to the investor consortium (the “Consortium”), and King & Wood Mallesons is serving as PRC legal counsel to the Consortium.

CI Financial Corp. Announces Final Results of Substantial Issuer Bid

Retrieved on:

Friday, April 5, 2024

Asset Management, Professional Services, Finance, Income tax, CI Financial, Share, TSX, CIX, Income Tax Act, Sale, News, Person

CI Financial Corp. (TSX: CIX) (“CI Financial” or the “Corporation”) today announced the final results of its substantial issuer bid (the “Offer”) under which it has purchased for cancellation 4,857,142 of its common shares (the “Shares”) at the purchase price of $17.50 per Share, for an aggregate purchase price of approximately $85 million.

Key Points:

CI Financial Corp. (TSX: CIX) (“CI Financial” or the “Corporation”) today announced the final results of its substantial issuer bid (the “Offer”) under which it has purchased for cancellation 4,857,142 of its common shares (the “Shares”) at the purchase price of $17.50 per Share, for an aggregate purchase price of approximately $85 million.
Shares purchased under the Offer represent approximately 3.11% of the issued and outstanding Shares at the time that the Offer was commenced.
Based on the final count by Computershare Investor Services Inc., the depositary for the Offer (the “Depositary”), a total of 12,586,530 Shares were properly tendered and not withdrawn.
To assist shareholders in determining the Canadian tax consequences of the Offer, CI Financial estimates that for the purposes of the Income Tax Act (Canada), the paid-up capital per Share is approximately $10.7284.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on:

Tuesday, April 2, 2024

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points:

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

Rubicon Receives Notice of Non-Compliance with NYSE Trading Share Price and Market Capitalization Listing Rules

Retrieved on:

Friday, March 22, 2024

Environment, Technology, Finance, Other Technology, Professional Services, Software, Data Management, Recycling, Artificial Intelligence, RBT, Share, Calendar, Medical device

The Notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE.

Key Points:

The Notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE.
The NYSE provides a period of six months (the “Share Price Cure Period”) following receipt of the Notice to regain compliance with the minimum stock price requirement for continued listing on the NYSE.
Rubicon can regain compliance at any time during the Share Price Cure Period if, on the last trading day of any calendar month during the Share Price Cure Period, Rubicon has: (i) a closing stock price of at least $1.00 and (ii) an average closing stock price of at least $1.00 over the 30-day trading period ending on the last trading day of that month.
Rubicon is currently evaluating its available options and developing a plan to regain compliance with the minimum global market capitalization requirement.

BITB Crosses $2 Billion in Assets, Generates Largest Inflows of Any Crypto Specialist1

Retrieved on:

Monday, March 11, 2024

Today, over 3,000 wealth teams, RIAs, family offices, and institutional clients trust Bitwise as their specialist partner in the crypto space.

Key Points:

Today, over 3,000 wealth teams, RIAs, family offices, and institutional clients trust Bitwise as their specialist partner in the crypto space.
Bitwise’s national team of crypto experts is available to meet with investment professionals any time and in person.
Bitwise’s product offerings include five other crypto-themed ETFs, the world’s largest crypto index fund, private placement funds, alpha solutions, and separately managed account (SMA) solutions.
As of March 8, 2024, Bitwise has experienced net inflows of $1.35 billion, Valkyrie has experienced net inflows of $264 million, and Grayscale has experienced net outflows of more than $10 billion.

Custodian Property Income REIT plc: Update on recommended all-share merger with abrdn Property Income Trust Limited

Retrieved on:

Wednesday, March 13, 2024

Person, RCF, Sale, Annual report, IPO, FCA, NTA, Share, Disclosure, Documentation, NAV2, FSMA, EPRA, API, ULR, Prospectus, Bloomberg, NAV, Risk, AGM, Policy, Failure, Holding company

The CREI Board notes the API portfolio weighting to industrials is only 48% (as a % of API's portfolio by income as at 31 December 2023)8.

Key Points:

The CREI Board notes the API portfolio weighting to industrials is only 48% (as a % of API's portfolio by income as at 31 December 2023)8.
The ULR specialist investment strategy for the combined group therefore would reflect a material divergence from the current API strategy.
The two principal drivers of earnings per share in a property investment company are rental income and cost of debt.
Data for the twelve months to 18 January 2024 (being the latest practicable date prior to the Recommended Merger Announcement).

Xanadu Mines Ltd (ASX Code: XAM) Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

Retrieved on:

Wednesday, March 6, 2024

Mining, Part, Disclosure, Mine, The Act, Placement, Share, Lease

Xanadu Mines advises that on 4 March 2024, it issued 15,185,328 fully paid ordinary shares at a price of $0.055 per share, to Jinping (Singapore) Mining Pte Ltd (a wholly owned indirect subsidiary of Zijin Group Mining Co. Ltd) pursuant to a Share subscription agreement signed on 8 December 2023 (New Shares).

Key Points:

Xanadu Mines advises that on 4 March 2024, it issued 15,185,328 fully paid ordinary shares at a price of $0.055 per share, to Jinping (Singapore) Mining Pte Ltd (a wholly owned indirect subsidiary of Zijin Group Mining Co. Ltd) pursuant to a Share subscription agreement signed on 8 December 2023 (New Shares).
the New Shares were issued without disclosure under Part 6D.2 of the Act;
this notice is being given under section 708A(5)(e) of the Act;
as at the date of this notice, Xanadu Mines has complied with:
the provisions of Chapter 2M of the Act as they apply to Xanadu Mines; and
sections 674 and 674A of the Act as they apply to Xanadu Mines; and
as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) or 708A(8) of the Act that is required to be set out in this notice.
The Company intends to rely on the exemption in section 602.1 of the TSX Company Manual in respect of the Placement as an Eligible Interlisted Issuer.

Technip Energies Announces Launch of Share Buy-Back Program

Retrieved on:

Thursday, February 29, 2024

Annual general meeting, Engineering & Technology, Treasury, Energy transition, AGM, Share, Energy, Security (finance)

Technip Energies (PARIS:TE) (the “Company”), a leading Engineering & Technology company for the Energy Transition, today announces the launch of a share buy-back program of up to €100 million (the “Share Buy-back Program”), with up to €70 million to be used to purchase common shares for cancellation and up to €30 million to be used to fulfill the Company's obligations under equity compensation plans.

Key Points:

Technip Energies (PARIS:TE) (the “Company”), a leading Engineering & Technology company for the Energy Transition, today announces the launch of a share buy-back program of up to €100 million (the “Share Buy-back Program”), with up to €70 million to be used to purchase common shares for cancellation and up to €30 million to be used to fulfill the Company's obligations under equity compensation plans.
The maximum number of shares that can be acquired under the Share Buy-back Program is 5 million shares.
Following renewal of the repurchase authorization, share repurchases under the Share Buy-back Program will be carried out pursuant to the authorization granted at the 2024 AGM.
The Company is not obligated to carry out the Share Buy-back Program, and, if commenced, the Share Buy-back Program may be suspended or discontinued at any time, for any reason and without previous notice, in accordance with applicable laws and regulations.

UChicago Medicine and the University of Chicago Collaborate with MDClone to Improve Healthcare Data Access for Clinical Care Insights and Research

Retrieved on:

Tuesday, March 5, 2024

Hospital, MD, University, Chicago Medical Society, Health, Knowledge, Global Television Network, Share, Research, Partnership

BEER-SHEVA, Israel, March 5, 2024 /PRNewswire/ -- MDClone, a leading analytics and synthetic data company, announced today that it has partnered with the University of Chicago and UChicago Medicine to establish an ADAMS Center, a unified data-driven epicenter for innovation, research, and quality improvement projects for the health system.

Key Points:

Partnership to establish ADAMS Center, enabling University to drive synergy, collaboration, and quicker insights across care and research teams.
ADAMS represents the innovation process of Ask, Discover, Act, Measure, and then Share, focused on generating quicker insights at scale by fostering synergy among teams.
MDClone is able to convert the data into reliable synthetic data to protect sensitive health information.
It will empower clinical teams to lead meaningful change to care delivery and to streamline research and quality improvement activity," said Tom Spiegel, MD, Chief Quality Officer for the UChicago Medicine health system.